Pall Teams Up with RITT to Advance Transplantation Science
Pall Teams Up with RITT to Advance Transplantation Science
EAST HILLS, NY, July 12, 2007-Pall Corporation (NYSE:PLL) announced the establishment of a collaborative sponsorship agreement with the Research in Immune Tolerance in Transplantation (RITT) program at the Toronto General Hospital (University Health Network) located in Toronto, Canada.
The research and development, training, and education activities that are the focus of this collaboration will take place in the RITT Industrial BioDevelopment Laboratory (http://www.ibdl.ca), a state of the art facility for biotherapeutic and bioassay processing and development. The RITT program is funded jointly by the Canadian federal government (Canada Foundation for Innovation), the province of Ontario (Ontario Research Foundation), and the Toronto General Hospital. The RITT program is headed by Dr. Gary Levy, the director of the Multi-Organ Transplant Program (MOT) at the University Health Network, and one of the world leaders in both transplantation research and clinical practice. The MOT is Canada’s largest organ transplantation program and one of the largest in North America.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
